Danielle M. Brander, MD

home / authors / danielle-m-brander-md

Articles

Acalabrutinib Improves Long-Term PFS in Patients With High-Risk CLL

June 26th 2023

Danielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.

Addressing Treatment Challenges in CLL

Danielle M. Brander, MD

June 8th 2020

$PI3K/Anti-CD20 Therapy for Relapsed/Refractory CLL$

PI3K/Anti-CD20 Therapy for Relapsed/Refractory CLL

Danielle M. Brander, MD

June 8th 2020

Treatment Options for Relapsed CLL

Danielle M. Brander, MD

June 8th 2020

MRD Assessment and Treatment Selection in CLL

Danielle M. Brander, MD

June 8th 2020

BTK Monotherapy as Frontline Treatment of CLL

Danielle M. Brander, MD

June 8th 2020

Frontline Targeted Therapy for CLL

Danielle M. Brander, MD

June 8th 2020

Impressions of a 73-Year-Old Man With Relapsed CLL

Danielle M. Brander, MD

June 8th 2020

A 73-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia

Danielle M. Brander, MD

June 8th 2020

Danielle M. Brander, MD, remarks on the appropriateness for targeted therapy as a treatment option for a 73-year-old man with relapsed chronic lymphocytic leukemia.

$Navigating Treatment Options for Patients With Relapsed/Refractory CLL$

Navigating Treatment Options for Patients With Relapsed/Refractory CLL

Danielle M. Brander, MD

July 17th 2018

Danielle M. Brander, MD, assistant professor of medicine at Duke University School of Medicine and member of the Duke Cancer Institute, discusses a major challenge in the field of chronic lymphocytic leukemia. She says the biggest challenge to overcome in the treatment of patients with CLL is navigating areas where research is not yet mature. 